Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, IMA

Esaote North America introduces the MyLabtmX8 Ultrasound System into Canada: A fully featured, premium imaging system to meet the most demanding clinical needs in the hospital or in the medical office


FISHERS, Ind., Jan. 19, 2021 /CNW/ -- Esaote North America announces that the MyLabtmX8 Ultrasound System has now been approved in Canada.

Previously approved by FDA in the USA, MyLab X8 expands the reach of the MyLab Ultrasound Product Line with a fully featured premium imaging solution, integrating the latest technologies and delivering superior image quality without compromising workflow or efficiency.

"The MyLab X8 Ultrasound System is uniquely suited for the demands of a myriad of applications, whether in the hospital or in the office," said Robert Lewis, President and General Manager at Esaote North America. "Esaote has a legacy of producing high quality imaging solutions that are accessible and incorporate advanced technologies. We are committed to developing fully featured and versatile imaging systems with unmatched efficiency and scalability."

Esaote has always invested in workflow-oriented design and collected several awards about innovative solutions, setting itself as one of the world's leading providers of diagnostic imaging solutions. MyLabtmX8 Ultrasound System includes two exclusive solutions, easyMode* and easyColor*, which simplify the number of parameters to be adjusted by the users and drive ultrasound image optimization in just 3 swipes, with improved efficiency and patient throughput as a result.  

A wide range of cutting-edge technologies is also available as options on MyLabtmX8: Virtual Navigator for fusion imaging, QElaXto shearwave elastography, very High-frequency probes as well as several automation tools like eScan, eDoppler and zero-click advanced functions.

About Esaote

Esaote North America, as part of the international Esaote Group, continues to develop and distribute innovative medical imaging systems, with the support of one of the world's leading medical imaging companies. Esaote S.p.A. is a leader in medical device manufacturing in the areas of ultrasound, dedicated MRI, and Healthcare IT. Esaote's headquarters are in Genoa, Italy with an international presence in 80 countries.

MyLab is a trademark of Esaote SpA. Technology and features are system/configuration dependent. Specifications are subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details on the MyLabtmX8 , please contact your Esaote sales representative.

Photo - https://mma.prnewswire.com/media/1421471/Esaote_MyLabX8.jpg  
Logo - https://mma.prnewswire.com/media/1421470/Esaote_North_America_Logo.jpg

 

SOURCE Esaote North America


These press releases may also interest you

at 09:27
all® free clear, the #1 detergent brand recommended by dermatologists for sensitive skin, today announced it is partnering with Dr. Lindsey Zubritsky ? a board certified dermatologist and one of social media's most-followed...

at 09:18
Innovations in patient care developed at Florida Cancer Specialists & Research Institute, LLC (FCS) will be presented at the Oncology Nursing Society 49th Annual Congress in Washington, DC, the largest global gathering dedicated to oncology nursing....

at 09:18
FORUS Therapeutics Inc. ("FORUS") is deeply disappointed and disagrees with the recent decision by the Honourable Christian Dubé, Minister of Health and Social Services in Quebec to deny listing XPOVIO® (selinexor) in combination with VELCADE®...

at 09:18
The Inception Company, trusted provider of meeting solutions to the life sciences industry and HCPs (healthcare professionals) for over 20 years and known for its Pandotm platform, announces a pivotal role expansion for its in-house Executive...

at 09:15
n-Lorem, a nonprofit foundation, announced a new partnership with Hongene Biotech Corporation that supports n-Lorem's efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1...

at 09:15
Synaptogenix, Inc. ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22,...



News published on and distributed by: